Table 1.

Clinical studies to evaluate new drugs targeting lipid-mediated pathways in the treatment of pulmonary fibrosis.

Drug	Target Specificity	Identifier a	Stage
BMS-986278	LPA1 receptor antagonist	NCT04308681	Phase II
BMS-986020	LPA1 receptor antagonist	NCT01766817	Phase II
18F-BMS-986327	LPA1 ligand for PET	NCT04069143	Phase I
Tipelukast/MN-001	Orphan drug (LT receptor, PDE inhibitor, 5-LO pathway)	NCT02503657	Phase II
GLPG1690	ATX inhibitor	NCT03733444	Phase III
BBT-877	ATX inhibitor	NCT03830125	Phase I
X-165	ATX inhibitor	Preclinical, IND	-
GSK2126458	PI3K/mTOR inhibitor	NCT01725139	Phase I
Sirolimus	mTOR inhibitor	NCT01462006	Phase I
HEC68498	PI3K/mTOR inhibitor	NCT03502902	Phase I

^a Unique identifier from https://clinicaltrials.gov/; ATX—Autotaxin; IND—Investigational new drug; LPA₁—Lysophosphatidic acid receptor type1; 5-LO—5-lipoxygenase; LT—Leukotriene; mTOR—mammalian target of rapamycin; PDE—Phosphodiesterase; PET—Positron emission tomography; PI3K—Phosphoinositide 3-kinase.